Pacira Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Pacira Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#265 of 15,742 sponsors by registered trial count).
Pacira Pharmaceuticals: 88 sponsored US clinical trials, 5 recruiting.
Pacira Pharmaceuticals sponsors 88 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 65 completed. 38 of these trials are in Phase 3-4 (later-stage) and 35 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Osteoarthritis of the Knee, with 4 trials.
Top-decile sponsor footprint
Pacira Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#265 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
65 of 82 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
88 total, page 1 of 2
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
NCT06884865
Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity
NCT06340451
Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery
NCT06271265
ZILRETTA in Subjects With Shoulder Osteoarthritis
NCT06269705
Innovations in Genicular Outcomes Registry
NCT05495334
Study to Evaluate the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee
NCT04119687
A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip
NCT06977568
Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers
NCT05456490
Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy
NCT05157841
Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty
NCT05139030
Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy
NCT04826328
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries
NCT04518462
Study to Evaluate Iovera®° in Adult Patients Undergoing Total Knee Arthroplasty
NCT04191031
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers
NCT04173611
Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation
NCT04293809
Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis
NCT04160091
Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries
NCT03927911
Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip
NCT04065074
Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy
NCT04002089
Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL
NCT03682302
Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section
NCT03853694
Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis
NCT03793010
Study in Adult Subjects Undergoing Posterolateral Thoracotomy
NCT03428984
Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee
NCT03529942
Study in Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL
NCT03485014
Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip
NCT03382262
Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA
NCT03378076
Treatment With Iovera° for Total Knee Arthroplasty (TKA) Post-Operative Pain
NCT03327220
Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections
NCT03176459
Phase 4, Controlled Study in Adult Subjects Undergoing Primary, 1-2 Level, Open Lumbar Spinal Fusion Surgery
NCT03015961
Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee
NCT03046446
PK Study of EXPAREL in Subjects Undergoing Open Spinal Fusion or Reconstructive Surgery
NCT02985762
Study of Local Administration of DepoTXA for Reduced Postsurgical Bleeding in Subjects Undergoing TKA
NCT02922582
Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty
NCT02713178
Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery
NCT02713230
Local Infiltration Analgesia With and Without EXPAREL Following Total Knee Arthroplasty
NCT02713490
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
NCT02762370
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
NCT02637323
Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction
NCT02517905
Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section
NCT02353754
Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee
NCT02468583
Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee
NCT02357459
Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty
NCT02284386
A Randomized, Study to Evaluate the Iovera° Device in Treating Pain Associated With Total Knee Arthroplasty
NCT02284113
Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain
NCT02260921
EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty
NCT02255500
Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy
NCT02199574
Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers
NCT02210247
Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee
NCT02116972
Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
NCT02003365
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 22 |
| Phase 3 | 17 |
| Phase 4 | 21 |
Therapeutic Areas
What is open in the Pacira Pharmaceuticals pipeline
5 recruiting of 88 indexed (6% open); 65 completed (74%).
Phase mix: 38 late (III/IV) vs 35 early (I/II) (balanced across stages).
Top condition: Osteoarthritis of the Knee (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Pacira Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 88 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Pacira Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 88 trials (± recruiting share)
- AbbVie (prior sponsor, Abbott) · 88 trials · 0% recruiting
- University of Medicine and Dentistry of New Jersey · 88 trials · 0% recruiting
- Abbott Nutrition · 89 trials · 1% recruiting
- Florida International University · 89 trials · 20% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Pfizer · 6% recruiting · 1,845 trials
- Boston College · 6% recruiting · 18 trials
- CytoDyn · 6% recruiting · 18 trials
- Dendreon · 6% recruiting · 18 trials
Related
What to do with this Pacira Pharmaceuticals page
88 registered trials is a research-attention snapshot, not an endorsement of Pacira Pharmaceuticals or any single study.
- 5 of Pacira Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Osteoarthritis of the Knee is the condition Pacira Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Osteoarthritis of the Knee trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Pacira Pharmaceuticals pipeline card: 88 registered trials from official public datasets.Report a data error.